Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

IGF-1 LR3 cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established IGF-1 LR3 cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. No human studies; no duration of human use has been studied 6.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • IGF-1 LR3 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established IGF-1 LR3 cycle length?
No. Human studies administered IGF-1 LR3 for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of IGF-1 LR3?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
IGF-1 LR3 dosing reference Full research page

References

  1. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency J Mol Endocrinol. 1992
  2. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys J Endocrinol. 1997
  3. Detection of His-tagged Long-R3-IGF-I in a black market product Growth Horm IGF Res. 2010
  4. Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice J Alzheimers Dis. 2025
  5. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Front Endocrinol (Lausanne). 2026
  6. ClinicalTrials.gov API search for "long R3" IGF (no registered studies returned on 23 October 2026) ClinicalTrials.gov. 2026
  7. Drugs@FDA application records for mecasermin (INCRELEX, application 021839, original approval 30 August 2005) openFDA / Drugs@FDA. 2026
  8. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (categories 1, 2 and 3; updated May 14, 2026) FDA. 2026
  9. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026